Tirzepitide+ is a once-per-week injectable, and is more potent than Semaglutide+
Pharmaceutical Chemistry Journal, 31 (10), 536-539
adults currently take a GLP-1 for weight loss (up from 3 percent in 2024 and 8 percent in 2025) 15 percent have used a GLP-1 medication for weight loss at some point 68 percent of current users take brand-name medications such as Ozempic, Wegovy, or Zepbound 19 percent take compounded or custom-mixed GLP-1 versions not approved by the FDA 91 percent of Americans now know GLP-1 drugs can be used for weight loss (up from 80 percent in 2024) The Medicare GLP-1 Bridge, administered by the Centers for Medicare and Medicaid Services (CMS), is a demonstration program operating outside the standard Part D benefit
Adjust dose or cancel anytime
[1] [2] These combined mechanisms help improve glycaemic control and often result in weight reduction as a secondary benefit
A Harvard Health report confirms that these symptoms are the most common complaints among GLP-1 users, with up to half of patients reporting discomfort